This guidance provides sponsors and investigators with recommendations on how to design investigations to assess the outcomes in pregnant women exposed to drug and biological products regulated by FDA in the postapproval setting.
This guidance provides sponsors and investigators with recommendations on how to design investigations to assess the outcomes in pregnant women exposed to drug and biological products regulated by FDA in the postapproval setting.
No comments yet. Be the first to share your thoughts.